Key Takeaway:
- FDA approves first gene therapy for rare genetic hearing loss caused by the OTOF mutation.
- Clinical trial shows significant hearing improvement in most treated children after a single dose.
- Regeneron will provide the therapy free to eligible U.S. patients, improving treatment access.
The U.S. Food and Drug Administration approved Regeneron’s Otarmeni as the First Gene Therapy for a rare inherited hearing loss on Thursday, offering new treatment hope for about 50 affected U.S. babies annually. Regeneron has announced it will provide the drug free of charge.
FDA Fast-Tracks First Gene Therapy For Genetic Deafness
The Food and Drug Administration approved Otarmeni, the first gene therapy designed to treat hearing loss caused by mutations in the OTOF gene, marking a major advance in genetic medicine.
The therapy targets a rare condition affecting roughly 50 newborns in the United States each year. Approval came through the Commissioner’s National Priority Voucher, an FDA pilot program aimed at accelerating reviews of breakthrough treatments.
“This really is life-changing for families with children with hearing loss,” said Dr. Eliot Shearer, a pediatric otolaryngologist at Boston Children’s Hospital and a principal investigator on the clinical trial.
Unlike traditional treatments, Otarmeni addresses the underlying genetic cause of deafness rather than compensating for hearing loss.
The therapy replaces the faulty OTOF gene responsible for producing otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. Without the protein, sound signals never reach the brain, resulting in profound hearing impairment.
Clinical Trial Shows Strong Hearing Improvement
The FDA based its approval on a clinical trial involving 20 children diagnosed with the OTOF mutation who received a single dose of the therapy in one or both ears.
Researchers reported improved hearing in 16 of the 20 participants. Five children developed the ability to detect whispers, suggesting significant restoration of auditory function.
Shearer said the results differ from cochlear implants, the only existing treatment for genetic deafness. While implants restore the ability to hear speech and music, they alter sound quality.
“With gene therapy, the improved hearing is on 24/7 and doesn’t rely on batteries,” Shearer said.
Doctors administer the treatment through a surgical procedure similar to cochlear implant surgery, delivering the therapy directly into the inner ear while the patient is under general anesthesia.
Reported side effects included middle-ear infection or inflammation, nausea, vomiting and dizziness. Researchers described the risks as manageable within standard surgical care.
Free Access Raises Questions About Cost And Global Availability
In an unusual move, Regeneron announced it will provide Otarmeni at no cost to eligible U.S. patients. The company, however, does not control expenses related to administering the therapy, which require specialized surgery.
The First Gene Therapy treatments often carry price tags reaching millions of dollars, but Otarmeni currently has no listed price outside the United States because it has not yet received international approval.
President Donald Trump highlighted the approval during an Oval Office announcement tied to a drug pricing agreement with Regeneron involving discounted medications offered through the TrumpRx self-pay platform.
Health policy experts praised the company’s decision to waive the drug’s cost.
“Regeneron has shown us that one option we can consider that will ensure affordable access for patients to these therapies is to not charge the health system for the therapy,” said Sarah Emond, president and CEO of the Institute for Clinical and Economic Review, a nonprofit that evaluates drug value and pricing.
Experts say the approval may signal broader adoption of gene therapies targeting inherited conditions once considered untreatable.
Visit Healthcare 360 Magazine For The Most Recent Information.
